Trial Profile
Pharmacokinetics and Tolerabilitynce Studies of Gentuximab (Recombinant Anti-VEGFR2 Human-mouse Chimeric Monoclonal Antibody) Injection in the Treatment of Late Recurrence of Metastatic Solid Tumors in China: An Open-label Non-randomised Uncontrolled Dose-escalation Single Center Pphase Ia Study in Patients With Late Recurrence of Metastatic Solid Tumors in China
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Gentuximab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GeneScience Pharmaceuticals
- 25 Oct 2017 New trial record